<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005914</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000642363</org_study_id>
    <secondary_id>P30CA069533</secondary_id>
    <secondary_id>OHSU-4913</secondary_id>
    <secondary_id>ENZON-OHSU-4913</secondary_id>
    <nct_id>NCT01005914</nct_id>
  </id_info>
  <brief_title>Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Phase II Trial of the Addition of PEG-Asparaginase to the Hyper-CVAD Regimen in Adult Newly-Diagnosed Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
      cells, either by killing the cells or by stopping them from dividing. Giving more than one
      drug (combination chemotherapy) may kill more cancer cells.

      PURPOSE: This phase II trial is studying the side effects of giving pegaspargase together
      with combination chemotherapy and to see how well it works in treating patients with newly
      diagnosed acute lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To estimate the complete response rate in patients with newly diagnosed acute
           lymphoblastic leukemia treated with pegaspargase in combination with hyper-CVAD regimen
           comprising cyclophosphamide, dexamethasone, vincristine sulfate, doxorubicin
           hydrochloride, methotrexate, and cytarabine.

        -  To determine the safety and tolerability of this regimen in these patients.

      Secondary

        -  To evaluate the progression-free survival and overall survival of patients treated with
           this regimen.

        -  To determine the half-life of pegaspargase when administered in combination with
           hyper-CVAD regimen.

        -  To monitor the development of neutralizing antibodies to pegaspargase when administered
           in combination with hyper-CVAD regimen.

        -  To assess minimal residual disease by flow cytometry at the end of courses 1A and 1B.

      OUTLINE: This is a multicenter study.

        -  Hyper-CVAD regimen (courses 1, 3, 5, and 7): Patients receive cyclophosphamide IV over
           2-3 hours twice daily on days 1-3, dexamethasone IV on days 1-4 and 11-14, methotrexate
           intrathecally (IT) on day 2, doxorubicin hydrochloride IV over 2 hours and pegaspargase
           IV over 1-2 hours on day 4, vincristine sulfate IV on days 4 and 11, and cytarabine IT
           on day 8.

        -  High-dose methotrexate/cytarabine regimen (courses 2, 4, 6, and 8): Patients receive
           methotrexate IV continuously over 24 hours on day 1, methylprednisolone IV twice daily
           on days 1-3, methotrexate IT on day 2, cytarabine IV over 2 hours twice daily on days 2
           and 3, pegaspargase IV over 1-2 hours on day 3, and cytarabine IT on day 8.

      Treatment repeats every 3-4 weeks for 8 courses in the absence of disease progression or
      unacceptable toxicity. Patients with Philadelphia chromosome-positive disease also receive
      oral imatinib mesylate daily beginning at diagnosis.

      Patients who complete 8 courses of chemotherapy and are not candidates for hematopoietic stem
      cell transplantation receive maintenance therapy off study.

      Blood samples are collected at baseline and periodically during study for pharmacokinetics
      and neutralizing antibody assays.

      After completion of study therapy, patients are followed up every 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Increased rate of bacterial infections
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate After Course 1 of Pegaspargase When Administered in Combination With Hyper-CVAD Regimen</measure>
    <time_frame>After day 4 of treatment</time_frame>
    <description>The complete response rate after 1A cycle of a PEG-Asparaginase and hyper-CVAD combination regimen will be estimated, and an exact 95% confidence interval will be computed using a binomial distribution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 3 and 4 Toxicity Associated With the Combination of Peg-Asparaginase and Hyper-CVAD Which Include: Allergic Reactions, Elevated Liver Enzymes, Hyperbilirubinemia, Hyperglycemia, Central Nervous System (CNS) Thrombosis, and Pancreatitis.</measure>
    <time_frame>The assessment of safety will be based mainly on the frequency of adverse events</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year Progression-free Survival</measure>
    <time_frame>After completion of 8 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Achieve Complete Response or Partial Response After Courses 1 and 2</measure>
    <time_frame>An interim analysis of safety is planned after the enrollment of 15 evaluable patients.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At least every 6 months until death.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Minimal Residual Disease</measure>
    <time_frame>End of cycles 1A and 1B</time_frame>
    <description>Cycle 1A: Days 1 through 14 Cycle 1B: Days 1 through 8, after the first 14 days of cycle 1A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of Pegaspargase</measure>
    <time_frame>The approximate tÂ½ in adult patients is 5.73 days. The half-life is independent of the dose administered, disease status, renal or hepatic function, age, or gender.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:cyclophosphamide Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
Drug:cytarabine Day 2 &amp; 3: 3g/m2 IV over 2 hours q12 X 4
Drug:dexamethasone Day 1-4; 11-14: 40 mg daily
Drug:doxorubicin hydrochloride Day 4: 50 mg/m2 IV over 2 hours
Drug:imatinib mesylate 600 mg/day
Drug:methotrexate Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
Drug: methylprednisolone Day 1-3: 50mg IV BID
Drug: pegaspargase Day 3/Day4: 2,500 IU/ m2 IV
Drug: vincristine sulfate Day 4 &amp; 11: 2 mg IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Cytoxan, Neosar, CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Day 2 &amp; 3: 3g/m2 IV over 2 hours q12 X 4</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Cytosar-U, Ara-C, Arabinosylcytosine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Day 1-4; 11-14: 40 mg daily</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Decadron, DexPak, dex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Day 4: 50 mg/m2 IV over 2 hours</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Adriamycin RDF, Adriamycin PFS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>600 mg/day</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Gleevec, Glivec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Trexall, Rheumatrex, MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>Day 1-3: 50mg IV BID</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Medrol, Depo-Medrol, Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
    <description>Day 3/Day4: 2,500 IU/ m2 IV</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Onscapar, PEG-L-asparaginase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Day 4 &amp; 11: 2 mg IV</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Marqibo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be newly diagnosed (untreated) with Acute Lymphoblastic Leukemia based
             on a bone marrow examination unless there is a contraindication to having the test
             performed. This includes precursor-B ALL, precursor-T ALL, and Philadelphia chromosome
             positive ALL. For reference, see criteria by Center for International Blood and Marrow
             Transplant Research (CIBMTR).&gt; 20% blasts on a bone marrow aspirate OR If a bone
             marrow aspirate is not obtained, the diagnosis of acute leukemia can be established by
             a pathologic diagnosis of acute leukemia on a bone marrow biopsy OR A complete blood
             count documenting the presence of at least 10,000 white blood cells (WBC)/Î¼l and at
             least 20% circulating blasts

          -  Adults, 18 to 60 years of age.

          -  Women of child bearing potential (WOCBP) must be willing to use adequate contraception
             to avoid pregnancy for the duration of study participation.

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2

          -  Adequate renal function defined as: Serum creatinine â¤ 2.0 x upper limit normal (ULN)
             for institution

          -  Adequate hepatic function defined as:Total bilirubin â¤ 2.0 x ULN for institution
             Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) â¤ 2.0 x ULN for
             institution

          -  Patient must have the ability to understand and the willingness to sign a written
             informed consent document. The patient and/or the patient's legally authorized
             guardian must acknowledge consent for treatment as a human subject on this study.

        Exclusion Criteria:

          -  Mature B (Burkitt's) ALL will be excluded.

          -  An active malignancy other than ALL (with the exception of basal and/or squamous cell
             skin cancers and curatively treated carcinoma of the cervix) within 5 past years of
             study entry.

          -  Documented central nervous system (CNS) involvement with leukemia will be excluded. A
             diagnostic lumbar puncture will not be part of screening procedures.

          -  Severe pulmonary, renal, or hepatic disease not related to the patient's ALL will be
             excluded.

          -  Cardiac dysfunction as defined by:Myocardial infarction within the last 6 months of
             study entry, or Reduced left ventricular function with an ejection fraction â¤50% as
             measured by Multigated Acquisition (MUGA) scan or echocardiogram at study entry,
             Unstable angina, Unstable cardiac arrhythmias, New York Heart Association (NYHA) Class
             III or IV heart failure, Electrocardiographic evidence of acute ischemia or active
             conduction system abnormalities

          -  Known or suspected human immunodeficiency virus (HIV)-positive patients are excluded
             from the study because of possible risk of lethal infection when treated with marrow
             suppressive therapy.

          -  Any concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled
             diabetes, infection, hypertension, etc.) or psychiatric illness that could, in the
             investigator's opinion, potentially interfere with the completion of treatment
             according to this protocol.

          -  Patients who have had chemotherapy or radiotherapy for ALL prior to entering the study
             will be excluded. Hydroxyurea and one dose of intravenous vincristine are allowed
             prior to registration for patient convenience. Prior steroid therapy is allowable, â¤5
             days prior to the start of the regimen.

          -  Patients may not have received any other investigational agents within the last 30
             days.

          -  WOCBP who are unwilling or unable to use an acceptable method of contraception for the
             entire study period. Pregnant or lactating women are excluded from this study because
             of possible risk to the fetus or infant. Women with a positive serum pregnancy test on
             enrollment or prior to study drug administration will be excluded.

          -  Men whose sexual partners are WOCBP, who are unwilling or unable to use an acceptable
             contraceptive method to avoid pregnancy of his partner for the entire study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon Hayes-Lattin</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2009</study_first_submitted>
  <study_first_submitted_qc>October 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2009</study_first_posted>
  <results_first_submitted>October 28, 2014</results_first_submitted>
  <results_first_submitted_qc>February 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2015</results_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adults</keyword>
  <keyword>Philadelphia chromosome precursor ALL,</keyword>
  <keyword>T-cell ALL</keyword>
  <keyword>untreated ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Drug:cyclophosphamide-Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3 Drug:cytarabine Day 2 &amp; 3: 3g/m2 IV over 2 hours q12 X 4 Drug:dexamethasone Day 1-4; 11-14: 40 mg daily Drug:doxorubicin hydrochloride Day 4: 50 mg/m2 IV over 2 hours Drug:imatinib mesylate 600 mg/day Drug:methotrexate Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion Drug: methylprednisolone Day 1-3: 50mg IV BID Drug: pegaspargase Day 3/Day4: 2,500 IU/ m2 IV Drug: vincristine sulfate Day 4 &amp; 11: 2 mg IV
cyclophosphamide: Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
cytarabine: Day 2 &amp; 3: 3g/m2 IV over 2 hours q12 X 4
dexamethasone: Day 1-4; 11-14: 40 mg daily
doxorubicin hydrochloride: Day 4: 50 mg/m2 IV over 2 hours
imatinib mesylate: 600 mg/day
methotrexate: D</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was not performed due to early termination of the study due to safety concerns.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Drug:cyclophosphamide Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3 Drug:cytarabine Day 2 &amp; 3: 3g/m2 IV over 2 hours q12 X 4 Drug:dexamethasone Day 1-4; 11-14: 40 mg daily
Drug:doxorubicin hydrochloride Day 4: 50 mg/m2 IV over 2 hours
Drug:imatinib mesylate 600 mg/day
Drug:methotrexate Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
Drug: methylprednisolone Day 1-3: 50mg IV BID
Drug: pegaspargase Day 3/Day4: 2,500 IU/ m2 IV
Drug: vincristine sulfate Day 4 &amp; 11: 2 mg IV
cyclophosphamide: Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
cytarabine: Day 2 &amp; 3: 3g/m2 IV over 2 hours q12 X 4
dexamethasone: Day 1-4; 11-14: 40 mg daily
doxorubicin hydrochloride: Day 4: 50 mg/m2 IV over 2 hours
imatinib mesylate: 600 mg/day
methotrexate: D</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.9" lower_limit="22" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Response Rate After Course 1 of Pegaspargase When Administered in Combination With Hyper-CVAD Regimen</title>
        <description>The complete response rate after 1A cycle of a PEG-Asparaginase and hyper-CVAD combination regimen will be estimated, and an exact 95% confidence interval will be computed using a binomial distribution.</description>
        <time_frame>After day 4 of treatment</time_frame>
        <population>Outcome Measure analysis was not performed due to early termination of the study due to safety concerns</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Cy D1- 3: 300 m g/m2 IV- 6 doses, mesna 600 mg/ m2 /day continuous IV D 1-3, ARAC D 2 &amp; 3: 3g/m2 IV q12 X 4, Dex D1-4; 11-14: 40 mg daily, doxorubicin hydrochloride D4: 50 mg/m2 IV, imatinib mesylate 600 mg/day, MTX D1: 1g/ m2 200 mg/ m2 load IV plus 800 mg/ m2, methylprednisolone D 1-3: 50mg IV BID, pegaspargase D3/D4: 2,500 IU/ m2 IV, vincristine sulfate D4 &amp; 11: 2 mg IV, Cy: D 1- 3: 300 m g/m2 IV 6 doses plus mesna 600 mg/ m2 /day, continuous infusion D 1-3. ARAC D 2 &amp; 3: 3g/m2 IV q12 X 4, dex: D 1-4; 11-14: 40 mg daily, doxorubicin hydrochloride: D 4: 50 mg/m2 IV, imatinib mesylate: 600 mg/day, MTX: D 1: 1g/ m2 200 mg/ m2load IV plus 800 mg/ m2 IV, methylprednisolone: D 1-3: 50mg IV BID, pegaspargase: D 3/D4: 2,500 IU/ m2 IV, vincristine sulfate: D 4 &amp; 11: 2 mg IV, pharmacological study: C1A: pre-dose between Days 1 to 4, C1A: D11 or 12., C1A: D18 or 19, C 1A: D25 or 26, C1A: D32 or 33 C1B: pre-dose between D1-3, C1B: D1 or 11 C1B: D17 or 18, C1B: D24 or 25 C1B: D31 or 32</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Rate After Course 1 of Pegaspargase When Administered in Combination With Hyper-CVAD Regimen</title>
          <description>The complete response rate after 1A cycle of a PEG-Asparaginase and hyper-CVAD combination regimen will be estimated, and an exact 95% confidence interval will be computed using a binomial distribution.</description>
          <population>Outcome Measure analysis was not performed due to early termination of the study due to safety concerns</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Grade 3 and 4 Toxicity Associated With the Combination of Peg-Asparaginase and Hyper-CVAD Which Include: Allergic Reactions, Elevated Liver Enzymes, Hyperbilirubinemia, Hyperglycemia, Central Nervous System (CNS) Thrombosis, and Pancreatitis.</title>
        <time_frame>The assessment of safety will be based mainly on the frequency of adverse events</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-year Progression-free Survival</title>
        <time_frame>After completion of 8 cycles</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Achieve Complete Response or Partial Response After Courses 1 and 2</title>
        <time_frame>An interim analysis of safety is planned after the enrollment of 15 evaluable patients.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>At least every 6 months until death.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Minimal Residual Disease</title>
        <description>Cycle 1A: Days 1 through 14 Cycle 1B: Days 1 through 8, after the first 14 days of cycle 1A</description>
        <time_frame>End of cycles 1A and 1B</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life of Pegaspargase</title>
        <time_frame>The approximate tÂ½ in adult patients is 5.73 days. The half-life is independent of the dose administered, disease status, renal or hepatic function, age, or gender.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All unexpected adverse events (AEs) related, probably related or possibly related to the study drug which are equal or greater than Grade 3 and serious adverse events (SAEs) were collected from first patient enrollment on 10/21/09 through 2010.</time_frame>
      <desc>Adverse events collected:
Unexpected AEs (when type or severity isn't listed in Expected AE List)
Deaths within 30 days of drug admin.
Grade â¥ 3 (related to the following):
Allergic reactions
CNS thrombosis/embolism
Coagulopathy
Elevated AST, ALT
Hyperbilirubinemia
Hyperglycemia
Hypertriglyceridemia
Pancreatitis</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>cyclophosphamide D1- 3: 300 m g/m2 IV 6 doses plus mesna 600 mg/ m2 /day cont. IV D1-3, cytarabine D2 &amp; 3: 3g/m2 IV, dexD1-4; 11-14: 40 mg daily, doxorubicin hydrochloride D4: 50 mg/m2 IV
Drug:imatinib mesylate 600 mg/day
Drug:methotrexate Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
Drug: methylprednisolone Day 1-3: 50mg IV BID
Drug: pegaspargase Day 3/Day4: 2,500 IU/ m2 IV
Drug: vincristine sulfate Day 4 &amp; 11: 2 mg IV
cyclophosphamide: Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
cytarabine: Day 2 &amp; 3: 3g/m2 IV over 2 hours q12 X 4
dexamethasone: Day 1-4; 11-14: 40 mg daily
doxorubicin hydrochloride: Day 4: 50 mg/m2 IV over 2 hours
imatinib mesylate: 600 mg/day
methotrexate: D</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenic fever</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>hypokalemia, hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>gastoenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>anaphylaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacillus species sepsis with encephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>fungemia, staph bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>gnr bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>acute epiglottitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>klebsiella bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>pneumonia (streptoccocus bacteremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>lung infection (fungal)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>alpha-hemolytic streptococcal bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination of the study due to adverse events.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Brandon Hayes-Lattin</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-494-1551</phone>
      <email>hayeslat@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

